Automated CDMO for regenerative medicine using iDEM technology to scale cell manufacturing at up to 50% lower cost than manual methods.
Mytos is an automated contract development and manufacturing organization (CDMO) for regenerative medicine, powered by its proprietary iDEM automation system. iDEM automates all unit operations in 2D T-flask cell culture, reducing labor per batch by up to 10x and cleanroom footprint by 10x compared to manual CDMOs, at up to 50% lower batch costs. The CDMO operates from a site within CGT Catapult's 80,000 sq ft facility and offers end-to-end services from process and analytical development to regulatory support, targeting clinical-stage programs for brain, eye, and bone indications. Mytos CDMO is a product of Mytos.